Patents by Inventor Hsien-Yu TSAI

Hsien-Yu TSAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEIN TARGETING PD-L1 AND NEUTRALIZING GAS6 AND USES THEREOF
    Publication number: 20240218337
    Abstract: The present disclosure relates to a fusion protein comprising a Gas6 binding portion and an antigen binding portion comprising an anti-PD-L1 antibody or antigen-binding fragment thereof. The present disclosure also relates to a method for treating and/or detecting a cancer in a subject in need, and a kit for detecting a cancer in a sample.
    Type: Application
    Filed: December 26, 2023
    Publication date: July 4, 2024
    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: CHU-BIN LIAO, HUI-CHIEH YU, HSIEN-YU TSAI, WEN-BIN KE, MENG-TING CAI
  • Antibodies specific to alpha-enolase and uses thereof
    Patent number: 10781266
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 22, 2020
    Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Po-Yin Lin, Ya-Wei Tsai, Chao-Yang Huang, Ying-Yung Lok, Chung-Hsiun Wu, Hsien-Yu Tsai, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
  • PEPTIDES DERIVED FROM KININOGEN-1 FOR PROTEIN DRUGS IN VIVO HALF-LIFE EXTENSIONS
    Publication number: 20190330376
    Abstract: A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.
    Type: Application
    Filed: December 29, 2017
    Publication date: October 31, 2019
    Applicant: Development Center for Biotechnology
    Inventors: Chen-Li Chien, Gregory Jiann Chen, Chuan-Lung Hsu, Jei-Hwa Yu, Hsien-Yu Tsai, Show-Shan Sheu, Wei-Jung Chang, Chia-Cheng Wu
  • ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND USES THEREOF
    Publication number: 20190322762
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Application
    Filed: March 19, 2018
    Publication date: October 24, 2019
    Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: SHIH-CHONG TSAI, TA-TUNG YUAN, SHIH-CHI TSENG, JIANN-SHIUN LAI, CHIA-CHENG WU, PO-YIN LIN, YA-WEI TSAI, CHAO-YANG HUANG, YING-YUNG LOK, CHUNG-HSIUN WU, HSIEN-YU TSAI, NENG-YAO SHIH, KO-JIUNN LIU, LI-TZONG CHEN
  • MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME
    Publication number: 20190309092
    Abstract: The present invention provides a modified antigen-binding Fab fragment. An antigen-binding molecule comprising the antigen-binding Fab fragment and a composition comprising the molecule are also provided.
    Type: Application
    Filed: July 20, 2017
    Publication date: October 10, 2019
    Applicant: Development Center for Biotechnology
    Inventors: Chih-Yung HU, Chao-Yang HUANG, Yu-Jung CHEN, Chia-Cheng WU, Chien-Tsun KUAN, Chia-Hsiang LO, Hsien-Yu TSAI